Dyadic International Inc. (NASDAQ: DYAI), a leading biotechnology firm, focuses on developing innovative microbial platforms to address the increasing global demand for protein bioproduction. Furthermore, the company aims to fulfil unmet clinical and industrial needs by providing cost-effective, accessible, and efficient biopharmaceutical products for both human and animal applications. 

Operating from the United States, this company has achieved success in developing a gene expression platform designed for the commercial synthesis of enzymes and various proteins. Utilizing this platform through licensing agreements, the company has leased it to Codexis, Inc. (NASDAQ: CDXS), BASF SE (OTCQX: BASFY, BASF.DE), Abengoa Bioenergy (OTC: AGOAF), and others in the past. In the past two years, the company has constructed another platform named Dapibus™, specifically designed to facilitate the production of metabolites, proteins, and other biological products for non-pharmaceutical applications. 

Recently, Rubic One Health, the African licensee of Dyadic International, entered into an agreement with Afreximbank to secure funding for a vaccine manufacturing project facility. The vaccines will be produced utilizing Dyadic’s C1 protein production platform, and manufacturing operations will take place in South Africa, with distribution planned across the entire continent. 

Devoted to assisting its collaborators and partners in creating impactful therapeutic and preventive treatments, the company extends its support to partners in both developed and emerging nations. Dyadic International is actively advancing its microbial platform technologies, which encompass DYAI-100, its candidate for a COVID-19 vaccine. Concurrently, the company is engaged in the progression of additional biologic candidates and vaccines. 

On November 20, a significant milestone occurred following the company’s disclosure of a partnership agreement signed by Rubic One Health, its African licensee. Dyadic International conveyed that Rubic One Health had entered into an agreement with Afreximbank to secure funding for the project preparation facility dedicated to vaccine manufacturing. The announcement highlighted that the vaccines would be produced utilizing Dyadic’s C1 protein production platform, with manufacturing operations set to take place in South Africa and distribution planned across the entire continent. 

Additionally, the company broadened its pre-existing licensing arrangement with South African-based Rubic One Health. Under the terms of this extended agreement, Rubic is set to utilize Dyadic International’s C1 platform for the exploration, development, and cost-effective, high-quality manufacturing of vaccines, catering to both human and animal use. The expanded licensing agreement emphasizes the distribution of these vaccines primarily in the African market. The recognition of the imperative to produce vaccines in Africa became evident with the signing of this deal by Rubic One Health.

Dyadic International, Inc. (NASDAQ: DYAI) is trading above is 30-day and 60-day averages at $1.58 and is position below its 20, 50, and 200-day moving averages, with a 52-week peak at $2.40, suggesting consolidation and signaling a potential transition to an upward trajectory. Considering these indicators, DYAI is a stock that warrants close monitoring in the current period and in the coming weeks.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com